Immune Design announces G100’s receipt of Orphan Drug designation by EMA
Immune Design announced that the European Medicines Agency has granted Orphan Drug Designation for G100, Immune Design's investigational intratumoral therapy, for the treatment of follicular non-Hodgkin's lymphoma. G100 has also been granted orphan drug designation by the UFDA. October 19, 2017